aTyr Pharma, Inc.

LIFE

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Efzofitimod 3 mg/kg	Phase 3	Pulmonary Sarcoidosis	-
Placebo	Phase 2	Facioscapulohumeral Muscular Dystrophy (FSHD)	-
ATYR1940	Phase 2	Limb-Girdle Muscular Dystrophies	-
efzofitimod 450 mg	Phase 2	Interstitial Lung Disease	-
Efzofitimod 1.0 mg/kg or Placebo	Phase 2	Pulmonary Sarcoidosis	-
Efzofitimod 1 mg/kg	Phase 2	SARS-CoV-2 (COVID-19) Severe Pneumonia	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

April 2026~efzofitimod 450 mg

Primary completion for efzofitimod 450 mg trial (NCT05892614) in Interstitial Lung Disease

Regulatory Approvals

LIFE News